Concentrix [CNXC] vs Genpact [G] Detailed Stock Comparison
Concentrix
NASDAQ
Loading...
Genpact
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Concentrix wins in 11 metrics, Genpact wins in 9 metrics, with 0 ties. Concentrix appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Concentrix | Genpact | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.99 | 14.51 | Concentrix |
| Price-to-Book Ratio | 0.70 | 2.94 | Concentrix |
| Debt-to-Equity Ratio | 135.96 | 59.21 | Genpact |
| PEG Ratio | -0.36 | 1.23 | Concentrix |
| EV/EBITDA | 6.03 | 10.34 | Concentrix |
| Profit Margin (TTM) | 2.54% | 10.92% | Genpact |
| Operating Margin (TTM) | 6.83% | 14.75% | Genpact |
| EBITDA Margin (TTM) | 6.83% | 14.75% | Genpact |
| Return on Equity | 5.85% | 21.86% | Genpact |
| Return on Assets (TTM) | 3.78% | 8.71% | Genpact |
| Free Cash Flow (TTM) | $428.73M | $530.19M | Genpact |
| Dividend Yield | 3.07% | 1.12% | Concentrix |
| 1-Year Return | -25.56% | 15.85% | Genpact |
| Price-to-Sales Ratio (TTM) | 0.31 | 1.54 | Concentrix |
| Enterprise Value | $8.51B | $8.47B | Concentrix |
| EV/Revenue Ratio | 0.88 | 1.72 | Concentrix |
| Gross Profit Margin (TTM) | 35.09% | 35.88% | Genpact |
| Revenue per Share (TTM) | $150 | $28 | Concentrix |
| Earnings per Share (Diluted) | $3.65 | $3.01 | Concentrix |
| Beta (Stock Volatility) | 0.58 | 0.93 | Concentrix |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Concentrix vs Genpact Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Concentrix | 4.90% | 8.05% | -14.47% | -7.35% | 12.90% | 19.59% |
| Genpact | 1.77% | 3.78% | -1.03% | 4.11% | -13.70% | 5.40% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Concentrix | -25.56% | -60.16% | -34.91% | -34.91% | -34.91% | -34.91% |
| Genpact | 15.85% | -2.81% | 6.09% | 93.38% | 220.44% | 187.68% |
Performance & Financial Health Analysis: Concentrix vs Genpact
| Metric | CNXC | G |
|---|---|---|
| Market Information | ||
| Market Cap | $2.99B | $7.61B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 566,426 | 2,005,413 |
| 90 Day Avg. Volume | 639,722 | 1,557,408 |
| Last Close | $52.07 | $45.31 |
| 52 Week Range | $36.28 - $77.00 | $37.82 - $56.76 |
| % from 52W High | -32.38% | -20.17% |
| All-Time High | $208.48 (Feb 07, 2022) | $56.76 (Feb 03, 2025) |
| % from All-Time High | -75.02% | -20.17% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.02% | 0.07% |
| Quarterly Earnings Growth | -0.37% | 0.09% |
| Financial Health | ||
| Profit Margin (TTM) | 0.03% | 0.11% |
| Operating Margin (TTM) | 0.07% | 0.15% |
| Return on Equity (TTM) | 0.06% | 0.22% |
| Debt to Equity (MRQ) | 135.96 | 59.21 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $67.99 | $14.84 |
| Cash per Share (MRQ) | $5.44 | $3.83 |
| Operating Cash Flow (TTM) | $713.97M | $649.51M |
| Levered Free Cash Flow (TTM) | $689.82M | $528.06M |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.07% | 1.12% |
| Last 12-Month Dividend | $1.62 | $0.47 |
Valuation & Enterprise Metrics Analysis: Concentrix vs Genpact
| Metric | CNXC | G |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.99 | 14.51 |
| Forward P/E | 3.85 | 12.66 |
| PEG Ratio | -0.36 | 1.23 |
| Price to Sales (TTM) | 0.31 | 1.54 |
| Price to Book (MRQ) | 0.70 | 2.94 |
| Market Capitalization | ||
| Market Capitalization | $2.99B | $7.61B |
| Enterprise Value | $8.51B | $8.47B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.88 | 1.72 |
| Enterprise to EBITDA | 6.03 | 10.34 |
| Risk & Other Metrics | ||
| Beta | 0.58 | 0.93 |
| Book Value per Share (MRQ) | $67.99 | $14.84 |
Financial Statements Comparison: Concentrix vs Genpact
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CNXC | G |
|---|---|---|
| Revenue/Sales | $2.37B | $1.25B |
| Cost of Goods Sold | $1.52B | $804.35M |
| Gross Profit | $855.90M | $450.07M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $168.87M | $179.40M |
| EBITDA | $334.50M | $215.90M |
| Pre-Tax Income | $100.79M | $176.74M |
| Income Tax | $30.54M | $44.02M |
| Net Income (Profit) | $70.26M | $132.72M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CNXC | G |
|---|---|---|
| Cash & Equivalents | $308.00M | $561.62M |
| Total Current Assets | $2.96B | $1.94B |
| Total Current Liabilities | $1.79B | $791.74M |
| Long-Term Debt | $4.90B | $1.36B |
| Total Shareholders Equity | $4.03B | $2.45B |
| Retained Earnings | $1.24B | $1.27B |
| Property, Plant & Equipment | $0 | $984.61M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CNXC | G |
|---|---|---|
| Operating Cash Flow | $231.10M | $189.46M |
| Capital Expenditures | $-55.79M | $-21.98M |
| Free Cash Flow | $180.74M | $17.86M |
| Debt Repayment | $-1.45B | $-8.97M |
| Common Stock Repurchase | $-46.82M | $-62.99M |
Short Interest & Institutional Ownership Analysis
| Metric | CNXC | G |
|---|---|---|
| Shares Short | 7.06M | 6.93M |
| Short Ratio | 10.29 | 5.37 |
| Short % of Float | 0.13% | 0.05% |
| Average Daily Volume (10 Day) | 566,426 | 2,005,413 |
| Average Daily Volume (90 Day) | 639,722 | 1,557,408 |
| Shares Outstanding | 64.24M | 174.66M |
| Float Shares | 35.84M | 159.76M |
| % Held by Insiders | 0.16% | 0.01% |
| % Held by Institutions | 0.97% | 1.05% |
Dividend Analysis & Yield Comparison: Concentrix vs Genpact
| Metric | CNXC | G |
|---|---|---|
| Last 12-Month Dividend | $1.62 | $0.47 |
| Last 12-Month Dividend Yield | 3.07% | 1.12% |
| 3-Year Avg Annual Dividend | $1.30 | $0.48 |
| 3-Year Avg Dividend Yield | 0.44% | 0.37% |
| 3-Year Total Dividends | $3.89 | $1.43 |
| Ex-Dividend Date | Jul 25, 2025 | Mar 11, 2025 |